Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 05, 2023 08:00 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals Announces Exploration of Strategic Alternatives

SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) (“Impel” or “the Company”), a commercial-stage biopharmaceutical company with a mission to develop transformative...
May 12, 2023 08:00 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor...
May 10, 2023 08:00 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ: IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering...
March 24, 2023 08:17 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to...
March 17, 2023 08:00 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023

SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...
March 03, 2023 16:01 ET | Source: Impel Pharmaceuticals

Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in March

SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from...
February 28, 2022 08:00 ET | Source: Impel NeuroPharma

Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
January 18, 2022 08:05 ET | Source: Impel NeuroPharma

Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights

Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable...
November 09, 2021 08:00 ET | Source: Impel NeuroPharma

Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference

SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...
November 08, 2021 08:00 ET | Source: Impel NeuroPharma

Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...